OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 4, 2010, Pages 606-612

  Advani, Anjali S ^a   Lim, Kathleen ^a   Gibson, Sarah ^b   Shadman, Mazyar ^a   Jin, Tao ^b   Copelan, Ed ^a   Kalaycio, Matt ^a   Sekeres, Mikkael A ^a   Sobecks, Ronald ^a   Hsi, Eric ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; BOB.1; Expression; OCT 2; Prognosis

Indexed keywords

ANTHRACYCLINE; BINDING PROTEIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN BCL 2; PROTEIN BOB.1; RETINOIC ACID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OCTAMER TRANSCRIPTION FACTOR-2; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77953188514     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003592735     Document Type: Article

References (19)

1. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
2. Gibson SE, Dong HY, Advani AS, Hsi ED. Expression of the B-cell associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia. Am J Clin Pathol 2006;126:916-924.
3. Latchman DS. The Oct-2 transcription factor. Int J Biochem Cell Biol 1996;28:1081-1083.
4. Shah PC, Bertolino E, Singh H. Using altered specificity Oct- 1 and Oct-2 mutants to analyze the regulation of immunoglobulin gene transcription. EMBO J 1997;16:1705-1717.
5. Luo Y, Roeder RG. Cloning, functional characterization, and mechanisms of action of the B-cell transcriptional coactivator OCA-B. Mol Cell Biol 1995;15:4115-4124.
6. Chang JF, Phillips K, Lundback T, Gstaiger M, Ladbury E, Luisi B. Oct-1 POU and octamer DNA co-operate to recognize the Bob-1 transcription co-activator via induced folding. J Mol Biol 1999;21:941-952.
7. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct-2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001;97:496-501.
8. Saez AI, Artiga MJ, Sanchez-Beato M, et al. Analysis of octamer-binding transcription factors Oct2 and Oct2 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol 2002; 15:211-220.
9. Libermann TA, Pan Z, Akbarali Y, et al. AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/ PAX5) in activation of the B cell-specific BLK gene promoter. J Biol Chem 1999;274:24671-24676.
10. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
11. Kalaycio M., Advani A, Pohlman B, et al. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol 2008;83:831-834.
12. Staudt LM, Clerc RG, Singh H, LeBowitz JH, Sharp PA, Baltimore D. Cloning of a lymphoid-specific cDNA encoding a protein binding the regulatory octamer DNA motif. Science 1998;241:577-580.
13. He X, Treacy MN, Simmons DM, Ingraham HA, Swanson LW, Rosenfeld MG. Expression of a large family of POUdomain regulatory genes in mammalian brain development. Nature 1989;340:35-41.
14. Kang SM, Tsang W, Doll S, et al. Induction of the POU domain transcription factor Oct-2 during T-cell activation by cognate antigen. Mol Cell Biol 1992;12:3149-3154.
15. Dunn TL, Ross IL, Hume DA. Transcription factor Oct-2 is expressed in primary murine macrophages. Blood 1996;88: 4072-4073.
16. Heckman CA, Duan H, Garcia PB, Boxer LM. Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 2006;25: 888-898.
17. Konig H, Pfisterer P, Corcoran LM,Wirth T. Identification of CD36 as the first gene dependent on the B-cell differentiation factor Oct-2. Genes Dev 1995;9:1598-1607.
18. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998;9:159-165.
19. Marcucci G, Moser B, Blum W, et al. A phase III randomized trial of intensive induction and consolidation chemotherapy +/7 oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients460 years old. Proc Am Soc Clin Oncol 2007;25:360s (Abstract 7012).